Skip to main content

Military Health System

Incidence of Sexually Transmitted Infections Before and After Insertion of an Intrauterine Device or Contraceptive Implant, Active Component Service Women, U.S. Armed Forces, 2014–2019

Recommended Content:

Medical Surveillance Monthly Report | Women's Health

Abstract

Long-acting reversible contraceptive (LARC) use has been increasing for almost 2 decades; however, while LARC methods are highly effective at preventing pregnancies, they do not prevent sexually transmitted infections (STIs). As a result, there is concern that the increased use of LARCs could lead to increased risk for STIs through sexual risk behaviors such as reduced condom use. Between 1 Jan. 2015 and 31 Dec. 2018, 18,691 service women in the study population received an intrauterine device (IUD) and 17,723 received an implant. Among active component service women who received an IUD or implant and maintained the same marital status during the study period, there was no notable increase in incidence of STIs in the 12 months after LARC insertion when compared to the 12 months before insertion. However, findings did show that rates of STIs increased from the LARC pre-insertion period to the post-insertion period among women in the youngest age category, suggesting that risk-reduction counseling and educational efforts should be focused on the youngest service members who receive LARC.

What Are the New Findings?

In general, among service women who began using LARC (an IUD or a contraceptive implant), incidence rates of STIs did not increase from the year before to the year after insertion. However, rates of STIs did increase after LARC insertion among women who were less than 20 years of age at the time of insertion.

What Is the Impact on Readiness and Force Health Protection?

Because STIs can negatively affect service members readiness and cause serious medical sequelae, the results of the study suggest that providers should emphasize to younger service women that LARC methods do not protect against STIs. Sexually active service members should be counseled that, for the prevention of STIs, condoms should be used along with LARCs.

Background

Long-acting reversible contraceptive (LARC) use, including subdermal hormonal implants and intrauterine devices (IUDs), has been increasing for almost 2 decades, from 1.5–2.5% of U.S. women of childbearing age in the early 2000s1,2 to 10.3–14.3% between 2009 and 2015.3–6IUDs initially fell out of favor when a design flaw in an early brand resulted in the deaths of 6 women and infections in thousands more,7but newer types have been found to be long-lasting, efficacious, and safe.1,8 Rates of use vary by subgroup, with women in their 20s and 30s1,3-5 and those with a higher parity1,2more likely to use a LARC method than their respective counterparts.

Among active component service women, a prior MSMR analysis indicated that LARC use increased from 17.2% to 21.7% between 2012 and 2016, mirroring the increasing trend observed in the general population.9LARC use among active component service women was most common among those aged 25–29 years,9,10 although an increase was seen across all age groups.9As in the civilian population, this increase is most likely related to the efficacy, longevity, and ease of use of LARCs. However, LARCs may have an additional appeal to female service members because of the ability of some LARCs to suppress menstruation,7,8,11 which may be advantageous in military operational environments.

While LARC methods are highly effective at preventing pregnancies, they do not prevent sexually transmitted infections (STIs). The increasing use of LARCs as an effective pregnancy prevention method has generated concern that their increased use both in U.S. civilian and military populations could increase risk for STIs through reduced use of condoms and increased high-risk behaviors, such as increased number of sexual partners. While some studies have reported lower rates of condom use among LARC users compared to women using other non-barrier contraceptive methods12–16 (particularly oral contraceptives15) and higher rates of STIs,13 others studies showed no difference in condom use between LARC users and users of the Depo-Provera injection, the patch, or the ring.17 Factors such as relationship status and number of partners may be related to dual-method use (i.e., use of both condoms and hormonal methods),16,18 as LARC users with a new partner19 and those with multiple partners18 have been shown to be more likely to report condom use than those without. Data from the contraceptive CHOICE project, a prospective cohort study of over 9,000 women who were offered the contraceptive method of their choice at no cost for 2–3 years, indicated that there was no difference in condom use or the number of partners before and after uptake of LARC.13,20 In addition, a recent systematic review reported no evidence of an association between LARC use and STIs, although the review noted a lack of prospective studies analyzing the relationship between contraceptive use and STI risk.21

A recent MSMR study showed that although the incidence of human papillomavirus (HPV) and genital herpes simplex virus (HSV) infections decreased among female service members during 2010–2018, the incidence of chlamydia and gonorrhea, the 2 most common bacterial STIs, increased,22 mirroring overall trends in the general U.S. population.23 STIs can negatively affect service members readiness and cause serious medical sequelae if untreated. Given the high, sustained burden of STIs and the uncertainty regarding the association between LARC use and STI risk among military service members, the objective of this analysis was to determine whether LARC initiation was associated with increased incidence of STIs among active component service women between 1 Jan. 2015 and 31 December 2018.

Methods

The surveillance population consisted of all active component service women of the Army, Navy, Marine Corps, or Air Force who received an IUD or implant between 1 Jan. 2015 and 31 Dec. 2018. Data for this study were ascertained from medical administrative and pharmacy data, as well as reports of notifiable medical events, routinely provided to the Armed Forces Health Surveillance Branch and maintained in the Defense Medical Surveillance System (DMSS) for surveillance purposes. STI cases were also derived from positive laboratory records in the Health Level 7 (HL7) chemistry and microbiology databases maintained by the Navy and Marine Corps Public Health Center at the EpiData Center.

Service women who received an IUD were identified as those who met any of the following criteria: 1) received a prescription for Mirena, Kyleena, Skyla, Paragard, or Liletta; 2) had a qualifying International Classification of Diseases, 9th or 10th Revision (ICD-9 or ICD-10, respectively) diagnosis code for IUD insertion (Table 1) in any diagnostic position; or 3) had a qualifying inpatient procedure code or outpatient Current Procedural Terminology (CPT) code for IUD insertion(Table 1) in any recorded position. Similarly, women who received an implant were identified as those who 1) received a prescription for Nexplanon or Implanon, 2) had a qualifying ICD-9 or ICD-10 diagnosis code for implant insertion (Table 1) in any diagnostic position, or 3) had a qualifying outpatient CPT code for implant insertion (Table 1) in any recorded position. Only the first documented insertion of each contraceptive type during the surveillance period was retained. If a woman had both an IUD and implant insertion during the study period, she was included in both groups.

Women were excluded from the IUD study population if they had an ICD-9 or ICD-10 diagnosis code or outpatient CPT code indicating IUD removal in the 12 months before or after the IUD insertion date (Table 2). Similarly, women were excluded from the implant study population if they had an outpatient CPT code indicating implant removal in the 12 months before or after the implant insertion date (Table 2). Women were excluded from the study population if they did not have continuous active component service time during the 12 months before or after the IUD or implant insertion. In addition, women were excluded if they changed their marital status at any time during the 12 months before or after the IUD or implant insertion.

Time-varying demographic and military characteristics including age, grade, service, military occupation, marital status, and education were measured at the time of the IUD or implant insertion. Receipt of short-acting reversible contraceptives (SARCs) was measured separately during the 12-month period before IUD or implant insertion and the 12-month period after IUD or implant insertion. Oral contraceptives, patches, and vaginal rings were defined by having a prescription record with therapeutic class code 681200 and a corresponding drug form code.24 Injectables were defined by having a prescription record for Depo-Provera or medroxyprogesterone acetate.

Incidence rates of STIs were measured during the period from 12 months to 1 month before IUD or implant insertion and in the 1 month to 12 months following IUD or implant insertion (full surveillance period: 1 Jan. 2014–31 Dec. 2019). A 30-day washout period before and after the IUD or implant insertion was used to account for any additional STI testing or short-term behavioral change that may have occurred during that period. An incident case of chlamydia, gonorrhea, or trichomoniasis was defined by having any of the following: 1) a case-defining diagnosis (Table 2) in the first or second diagnostic position of a record of an outpatient or in-theater medical encounter, 2) a confirmed notifiable disease report (applies only to chlamydia and gonorrhea), or 3) a positive laboratory test for any specimen source or test type. An individual could be counted as having a subsequent case only if there were more than 30 days between the dates on which the case-defining diagnoses were recorded. Incidence rates of STIs during the pre- and post-insertion periods were calculated per 1,000 service women. Crude confidence intervals were calculated in SAS/STAT software, version 9.4 (2014, SAS Institute, Cary, NC) using PROC GENMOD.

Results

During the study period, 18,691 service women who met inclusion criteria received an IUD and 17,723 received an implant (Table 3). Most of the women who received an IUD were aged 20–24 years (32.8%) or 25–29 years (26.2%). Half of the women who received an IUD were non-Hispanic white, and more than half were single and never married (54.0%) and had a high school education or less (59.0%). Women who received an IUD were more likely to be in the Navy (35.8%), junior enlisted rank (52.0%), and in communications/intelligence occupations (27.9%). A little less than half (44.2%) of women were using any type of SARC before IUD insertion, which dropped to 12.2% after IUD insertion. The most commonly dispensed SARC in the pre- and post-IUD insertion periods were oral contraceptives (34.4% and 10.0%, respectively).

Most of the women who received an implant were aged 20 years or less (41.9%) or 20–24 years (33.5%). Women with implants were predominantly non-Hispanic white (40.5%), single and never married (74.3%), and had a high school education or less (80.0%). Similar to those who received an IUD, women who received an implant were more likely to be in the Navy (42.9%) and junior enlisted rank (78.6%). Before implant insertion, a little more than one-third (34.7%) of women used any type of SARC, which dropped to 13.1% after implant insertion. The most commonly dispensed SARC in the pre- and post-implant insertion periods were oral contraceptives (25.2% and 11.7%, respectively).

Among women in the study population who received an IUD, the incidence rates of chlamydia, gonorrhea, and trichomoniasis were generally similar before and after IUD insertion, although rates of chlamydia and gonorrhea increased slightly (Table 4). Incidence rates of chlamydia were 42.5 per 1,000 women before IUD insertion (n=795) and 44.1 per 1,000 women after insertion (n=825). Incidence rates of gonorrhea were 3.3 per 1,000 women (n=62) before insertion and 4.4 per 1,000 women after insertion (n=82). Incidence rates of trichomoniasis remained the same before and after IUD insertion (2.8 per 1,000 [n=53] and 2.8 per 1,000 [n=52], respectively). Taken together, the incidence of any of the 3 STIs was 48.7 per 1,000 before IUD insertion and 51.3 per 1,000 after IUD insertion (incidence rate ratio [IRR]=1.05; 95% confidence interval [CI]: 0.95–1.16).

Among women in the study population who received an implant, the incidence rate of chlamydia increased slightly, the rate of gonorrhea decreased slightly, and the rate of trichomoniasis remained similar before and after implant insertion (Table 5). Incidence rates of chlamydia were 65.2 per 1,000 before implant insertion (n=1,155) and 68.2 per 1,000 after insertion (n=1,209). Incidence rates of gonorrhea were 5.5 per 1,000 women (n=97) before insertion and 4.4 per 1,000 after insertion (n=78). Incidence rates of trichomoniasis were 3.2 per 1,000 before implant insertion (n=56) and 3.2 per 1,000 after implant insertion (n=57). Taken together, the incidence of any of the 3 STIs was 73.8 per 1,000 before implant insertion and 75.8 per 1,000 after implant insertion (IRR=1.03; 95% CI: 0.95–1.12).

The incidence rates of any STI after IUD or implant insertion compared to before insertion varied by subgroup. Among women who were less than 20 years of age at the time of IUD or implant insertion, there was an increase in the rate of STIs after insertion, while women in all other age groups showed a decrease or no change in rates. Women who were less than 20 years of age at the time of LARC insertion had 1.61 times the rate of any STI infection after IUD insertion compared to before insertion (95% CI: 1.37–1.89) and 1.38 times the rate of any STI infection after implant insertion compared to before insertion (95% CI: 1.24–1.54) (Tables 6 and 7).

Editorial Comment

This study demonstrated that among active component service women who received an IUD or implant and maintained the same marital status during the study period, there was not a notable increase in incidence of STIs from the year before insertion to the year after insertion. This finding suggests that there is not a significant change in sexual risk behaviors among service women overall from before to after receiving an IUD or implant. While the current analysis is unable to ascertain the reasons for this finding, it could be that the number of partners for women choosing a LARC method did not change pre- and post-insertion and/or that LARC users with new or multiple partners increased or continued condom use, as suggested by some previous studies.13,18–20 However, the finding that rates did increase from pre- to post-IUD and implant insertion among women in the youngest age category suggests that risk-reduction counseling and educational efforts should be focused on the youngest service members who receive LARC. This is particularly important given that service women in the youngest age categories have the highest numbers of self-reported sexual risk behaviors, including numbers of new and multiple sexual partners.25 Providers who prescribe LARCs to young service women should emphasize that they do not protect against STIs and that condoms should continue to be used in addition to their contraceptive method of choice.

Overall rates of chlamydia and gonorrhea among women who received an IUD were approximately similar to rates observed in the overall female active component population.22 In contrast, overall rates of chlamydia and gonorrhea among women who received an implant were somewhat higher; however, women who received an implant were more likely to be younger and single and never married as compared with women who received an IUD, and these are known risk factors for STIs in the overall active component female population.22 It is worth mentioning that, historically, there has been concern regarding whether IUDs increase the risk of pelvic inflammatory disease (PID) among women with STIs; however, studies have indicated that the risk for PID among women who screened positive for chlamydia or gonorrhea and underwent concurrent IUD insertion is low,8,14 and current guidelines from the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists state that insertion should not be delayed while awaiting STI screening results.8,26

When the barriers to access are removed, women tend to choose LARC methods over other methods.13,20 LARC use has been shown to be increasing among service women and this trend will likely continue as both a method of pregnancy prevention and also potentially for menstrual suppression, which has operational benefits.9,11 One survey-based study of 500 Army women indicated that the majority (85%) expressed a desire to learn more about contraceptive options for menstrual suppression.27 Similarly, a recent article discussing menstrual suppression among female astronauts on longer missions also highlighted the benefits of some LARC methods in environments where menstrual suppression is beneficial.28 One LARC option for menstrual suppression is the use of levonorgestrel-releasing IUDs for longer than 12 months, which has been shown to substantially reduce the volume of menstrual blood, with 20% of women achieving amenorrhea.29

There are several limitations of this analysis to consider. The study intended to measure whether risk for STIs changed after IUD or implant insertion as a result of a hypothesized increase in sexual risk behaviors such as reduced use of condoms. However, data on sexual risk behaviors including number and type of sexual partners and condom usage were unavailable. Women were excluded from the population if their marital status changed after IUD or implant insertion, which was done to eliminate the potential confounding effect of a significant change in sexual partner status during the observation periods. Because this study utilized a self-controlled case series design in which the same women comprised the "before" and "after" IUD or implant population, nontime-varying covariates such as race/ethnicity are controlled for in the study design.30 However, changes in other demographic or military characteristics such as service branch, occupation, and rank in the year before and after IUD or implant insertion were not accounted for, although it is unlikely that these characteristics would change significantly to affect sexual risk behaviors over the course of the 2-year surveillance period for the majority of the study population.

Providers should continue to recommend LARCs to service women who ask for them. However, providers should also continue to emphasize that LARC methods do not protect against STIs and recommend that condoms be used along with LARCs, especially for younger female service members. No additional STI screening is needed before IUD insertion, and IUDs can be inserted at the time of screening.8,26 More information about sexual health and LARCs, including clinician training resources, is available through the Navy and Marine Corps Public Health Center's Sexual Health and Responsibility Program (SHARP) at https://www.med.navy.mil/sites/nmcphc/health-promotion/reproductive-sexual-health/Pages/larc.aspx.

References

  1. Branum AM, Jones J. Trends in long-acting reversible contraception use among U.S. women aged 15–44. NCHS Data Brief. 2015;188:1–8.
  2. Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007–2009. Fertil Steril. 2012;98(4):893–897.
  3. Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2015–2017. NCHS Data Brief. 2018;327:1–8. 
  4. Guttmacher Institute. Contraceptive use in the United States. https://www.guttmacher.org/factsheet/contraceptive-use-united-states. Accessed 15 Nov. 2019.
  5. Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012. Obstet Gynecol. 2015;126(5):917–927.
  6. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14–21.
  7. Shoupe D. LARC method: entering a new age of contraception and reproductive health. Contracept Reprod Med.2016;1:4.
  8. Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017;130(5):e251-e269.
  9. Stahlman S, Witkop CT, Clark LL, Taubman SB. Contraception among active component service women, U.S. Armed Forces, 2012–2016. MSMR. 2017;24(11):10–21.
  10. Witkop CT, Webber BJ, Chu KM, Clark LL. Contraception use among U.S. servicewomen: 2008–2013. Contraception. 2017;96(1):47–53.
  11. Christopher LA, Miller L. Women in war: operational issues of menstruation and unintended pregnancy. Mil Med. 2007;172(1):9–16.
  12. El Ayadi AM, Rocca CH, Kohn JE, et al. The impact of an IUD and implant intervention on dual method use among young women: Results from a cluster randomized trial. Prev Med. 2017;94:1–6.
  13. McNicholas CP, Klugman JB, Zhao Q, Peipert JF. Condom use and incident sexually transmitted infection after initiation of long-acting reversible contraception. Am J Obstet Gynecol. 2017:217(6);672.e1–672.e6.
  14. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt). 2015;24(5):354–359.
  15. Eisenberg DL, Allsworth JE, Zhao Q, Peipert JF. Correlates of dual-method contraceptive use: an analysis of the National Survey of Family Growth (2006–2008). Infect Dis Obstet Gynecol. 2012. https://www.hindawi.com/journals/idog/2012/717163/. Accessed 02 March 2020.
  16. Thompson EL, Vamos CA, Griner SB, Logan R, Vázquez-Otero C, Daley EM. Sexually transmitted infection prevention with long-acting reversible contraception: factors associated with dual use. Sex Transm Dis. 2018;45(4):e19.
  17. Steiner RJ, Liddon N, Swartzendruber AL, Rasberry CN, Sales JM. Long-acting reversible contraception and condom use among female US high school students: implications for sexually transmitted infection prevention. JAMA Pediatr. 2016;170(5):428–434.
  18. Williams RL, Fortenberry JD. Dual use of long-acting reversible contraceptives and condoms among adolescents. J Adolesc Health. 2013;52(4 suppl):s29–34.
  19. Bastow B, Sheeder J, Guiahi M, Teal S. Condom use in adolescents and young women following initiation of long- or short-acting contraceptive methods. Contraception. 2018;97(1):70–75.
  20. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol. 2014;57(4):635–643.
  21. Deese J, Pradhan S, Goetz H, Morrison C. Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives. Open Access J Contracept. 2018;9:91–112.
  22. Stahlman S, Seliga N, Oetting AA. Sexually transmitted infections, active component, U.S. Armed Forces, 2010–2018. MSMR. 2019;26(3):2–10.
  23. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2018. https://www.cdc.gov/std/stats18/default.htm. Accessed 12 Feb. 2020.
  24. Executive Office of Health and Human Services, State of Rhode Island. Dose form reference guide. http://www.eohhs.ri.gov/Portals/0/Uploads/Documents/Pharmacy/dose_form_ref_guide.pdf. Accessed 18 Feb. 2020.
  25. Meadows S, Engel CC, Collins RL, et al. 2015 Department of Defense Health Related Behaviors Survey (HRBS). Rand Health Q. 2018;8(2):5.
  26. Centers for Disease Control and Prevention. US selected practice recommendations for contraceptive use, 2016. Intrauterine contraception. https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/intrauterine.html. Accessed 18 Feb. 2020.
  27. Powell-Dunford NC, Cuda AS, Moore JL, Crago MS, Kelly AM, Deuster PA. Menstrual suppression for combat operations: advantages of oral contraceptive pills. Womens health issues. 2001;21(1):86–91.
  28. Jain V, Wotring VE. Medically induced amenorrhea in female astronauts. NPJ Microgravity. 2016;2:16008.
  29. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49(1):56–72.
  30. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515.

ICD-9 and ICD-10 diagnostic and procedure codes and CPT codes for LARC insertion and removal

 STI case defining ICD-9 and ICD-10 codes

 Demographic and military characteristics at the time of first-ever LARC placement, active component service women, U.S. Armed Forces,1 Jan. 2015–31 Dec. 2018

Incidence of STIs during pre- and post-IUD placement, active component service women, U.S. Armed Forces, 1 January 2014–31 Dec. 2019

Incidence of STIs during pre- and post-implant placement, active component service women, U.S. Armed Forces, 1 January 2014–31 Dec. 2019

 Incidence of any STI during pre- and post-IUD placement, active component service women, U.S. Armed Forces, 1 January 2014–31 Dec. 2019

Incidence of any STI during pre- and post-implant placement, active component service women, U.S. Armed Forces, 1 January 2014–31 Dec. 2019

You also may be interested in...

Incidence, Timing, and Seasonal Patterns of Heat Illnesses During U.S. Army Basic Combat Training, 2014–2018

Article
4/1/2019
U.S. Marines participate in morning physical training during a field exercise at Marine Corps Base Camp Pendleton, California. (Photo Courtesy: U.S. Marine Corps)

Risk factors for heat illnesses (HIs) among new soldiers include exercise intensity, environmental conditions at the time of exercise, a high body mass index, and conducting initial entry training during hot and humid weather when recruits are not yet acclimated to physical exertion in heat. This study used data from the Defense Health Agency’s–Weather-Related Injury Repository to calculate rates and to describe the incidence, timing, and geographic distribution of HIs among soldiers during U.S. Army basic combat training (BCT). From 2014 through 2018, HI events occurred in 1,210 trainees during BCT, resulting in an overall rate of 3.6 per 10,000 BCT person-weeks (p-wks) (95% CI: 3.4–3.8). HI rates (cases per 10,000 BCT p-wks) varied among the 4 Army BCT sites: Fort Benning, GA (6.8); Fort Jackson, SC (4.4); Fort Sill, OK (1.8); and Fort Leonard Wood, MO (1.7). Although the highest rates ofHIs occurred at Fort Benning, recruits in all geographic areas were at risk. The highest rates of HI occurred during the peak training months of June through Sept., and over half of all HI cases affected soldiers during the first 3 weeks of BCT. Prevention of HI among BCT soldiers requires relevant training of both recruits and cadre as well as the implementation of effective preventive measures.

Recommended Content:

Medical Surveillance Monthly Report

Update: Exertional Hyponatremia, Active Component, U.S. Armed Forces, 2003–2018

Article
4/1/2019
Drink water the day before and during physical activity or if heat is going to become a factor. (Photo Courtesy: U.S. Air Force)

From 2003 through 2018, there were 1,579 incident diagnoses of exertional hyponatremia among active component service members, for a crude overall incidence rate of 7.2 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, females, those less than 20 years old, and recruit trainees had higher overall incidence rates of exertional hyponatremia diagnoses. The overall incidence rate during the 16-year period was highest in the Marine Corps, intermediate in the Army and Air Force, and lowest in the Navy. Overall rates during the surveillance period were highest among Asian/Pacific Islander and non-Hispanic white service members and lowest among non-Hispanic black service members. Between 2003 and 2018, crude annual incidence rates of exertional hyponatremia peaked in 2010 (12.7 per 100,000 p-yrs) and then decreased to 5.3 cases per 100,000 p-yrs in 2013 before increasing in 2014 and 2015. The crude annual rate in 2018 (6.3 per 100,000 p-yrs) represented a decrease of 26.5% from 2015. Service members and their supervisors must be knowledgeable of the dangers of excessive water consumption and the prescribed limits for water intake during prolonged physical activity (e.g., field training exercises, personal fitness training, and recreational activities) in hot, humid weather.

Recommended Content:

Medical Surveillance Monthly Report

Update: Exertional Rhabdomyolysis, Active Component, U.S. Armed Forces, 2014–2018

Article
4/1/2019
U.S. Marines sprint uphill during a field training exercise at Marine Corps Air Station Miramar, California. to maintain contact with an aviation combat element, teaching and sustaining their proficiency in setting up and maintaining communication equipment.  (Photo Courtesy: U.S. Marine Corps)

Among active component service members in 2018, there were 545 incident diagnoses of rhabdomyolysis likely due to exertional rhabdomyolysis, for an unadjusted incidence rate of 42.0 cases per 100,000 person-years. Subgroup-specific rates in 2018 were highest among males, those less than 20 years old, Asian/Pacific Islander service members, Marine Corps and Army members, and those in combat-specific or “other/unknown” occupations. During 2014–2018, crude rates of exertional rhabdomyolysis increased steadily from 2014 through 2016 after which rates declined slightly in 2017 before increasing again in 2018. Compared to service members in other race/ethnicity groups, the overall rate of exertional rhabdomyolysis was highest among non-Hispanic blacks in every year except 2018. Overall and annual rates were highest among Marine Corps members, intermediate among those in the Army, and lowest among those in the Air Force and Navy. Most cases of exertional rhabdomyolysis were diagnosed at installations that support basic combat/recruit training or major ground combat units of the Army or the Marine Corps. Medical care providers should consider exertional rhabdomyolysis in the differential diagnosis when service members (particularly recruits) present with muscular pain or swelling, limited range of motion, or the excretion of dark urine (possibly due to myoglobinuria) after strenuous physical activity, particularly in hot, humid weather.

Recommended Content:

Medical Surveillance Monthly Report

Update: Heat Illness, Active Component, U.S. Armed Forces, 2018

Article
4/1/2019
Drink water the day before and during physical activity or if heat is going to become a factor. (Photo Courtesy: U.S. Air Force)

In 2018, there were 578 incident diagnoses of heat stroke and 2,214 incident diagnoses of heat exhaustion among active component service members. The overall crude incidence rates of heat stroke and heat exhaustion diagnoses were 0.45 cases and 1.71 cases per 1,000 person-years, respectively. In 2018, subgroup-specific rates of incident heat stroke diagnoses were highest among males and service members less than 20 years old, Asian/Pacific Islanders, Marine Corps and Army members, recruit trainees, and those in combat-specific occupations. Subgroup-specific incidence rates of heat exhaustion diagnoses in 2018 were notably higher among service members less than 20 years old, Asian/Pacific Islanders, Army and Marine Corps members, recruit trainees, and service members in combat-specific occupations. During 2014–2018, a total of 325 heat illnesses were documented among service members in Iraq and Afghanistan; 8.6% (n=28) were diagnosed as heat stroke. Commanders, small unit leaders, training cadre, and supporting medical personnel must ensure that the military members whom they supervise and support are informed about the risks, preventive countermeasures, early signs and symptoms, and first-responder actions related to heat illnesses.

Recommended Content:

Medical Surveillance Monthly Report

Vasectomy and Vasectomy Reversals, Active Component, U.S. Armed Forces, 2000–2017

Article
3/1/2019
Sperm is the male reproductive cell  Photo: iStock

During 2000–2017, a total of 170,878 active component service members underwent a first-occurring vasectomy, for a crude overall incidence rate of 8.6 cases per 1,000 person-years (p-yrs). Among the men who underwent incident vasectomy, 2.2% had another vasectomy performed during the surveillance period. Compared to their respective counterparts, the overall rates of vasectomy were highest among service men aged 30–39 years, non-Hispanic whites, married men, and those in pilot/air crew occupations. Male Air Force members had the highest overall incidence of vasectomy and men in the Marine Corps, the lowest. Crude annual vasectomy rates among service men increased slightly between 2000 and 2017. The largest increases in rates over the 18-year period occurred among service men aged 35–49 years and among men working as pilots/air crew. Among those who underwent vasectomy, 1.8% also had at least 1 vasectomy reversal during the surveillance period. The likelihood of vasectomy reversal decreased with advancing age. Non-Hispanic black and Hispanic service men were more likely than those of other race/ethnicity groups to undergo vasectomy reversals.

Recommended Content:

Medical Surveillance Monthly Report

Testosterone Replacement Therapy Use Among Active Component Service Men, 2017

Article
3/1/2019
Image of Marines carrying a wooden log for physical fitness. Click to open a larger version of the image.

This analysis summarizes the prevalence of testosterone replacement therapy (TRT) during 2017 among active component service men by demographic and military characteristics. This analysis also determines the percentage of those receiving TRT in 2017 who had an indication for receiving TRT using the 2018 American Urological Association (AUA) clinical practice guidelines. In 2017, 5,093 of 1,076,633 active component service men filled a prescription for TRT, for a period prevalence of 4.7 per 1,000 male service members. After adjustment for covariates, the prevalence of TRT use remained highest among Army members, senior enlisted members, warrant officers, non-Hispanic whites, American Indians/Alaska Natives, those in combat arms occupations, healthcare workers, those who were married, and those with other/unknown marital status. Among active component male service members who received TRT in 2017, only 44.5% met the 2018 AUA clinical practice guidelines for receiving TRT.

Recommended Content:

Medical Surveillance Monthly Report

Brief Report: Male Infertility, Active Component, U.S. Armed Forces, 2013–2017

Article
3/1/2019
Sperm is the male reproductive cell  Photo: iStock

Infertility, defined as the inability to achieve a successful pregnancy after 1 year or more of unprotected sexual intercourse or therapeutic donor insemination, affects approximately 15% of all couples. Male infertility is diagnosed when, after testing both partners, reproductive problems have been found in the male. A male factor contributes in part or whole to about 50% of cases of infertility. However, determining the true prevalence of male infertility remains elusive, as most estimates are derived from couples seeking assistive reproductive technology in tertiary care or referral centers, population-based surveys, or high-risk occupational cohorts, all of which are likely to underestimate the prevalence of the condition in the general U.S. population.

Recommended Content:

Medical Surveillance Monthly Report

Sexually Transmitted Infections, Active Component, U.S. Armed Forces, 2010–2018

Article
3/1/2019
Anopheles merus

This report summarizes incidence rates of the 5 most common sexually transmitted infections (STIs) among active component service members of the U.S. Armed Forces during 2010–2018. Infections with chlamydia were the most common, followed in decreasing order of frequency by infections with genital human papillomavirus (HPV), gonorrhea, genital herpes simplex virus (HSV), and syphilis. Compared to men, women had higher rates of all STIs except for syphilis. In general, compared to their respective counterparts, younger service members, non-Hispanic blacks, soldiers, and enlisted members had higher incidence rates of STIs. During the latter half of the surveillance period, the incidence of chlamydia and gonorrhea increased among both male and female service members. Rates of syphilis increased for male service members but remained relatively stable among female service members. In contrast, the incidence of genital HPV and HSV decreased among both male and female service members. Similarities to and differences from the findings of the last MSMR update on STIs are discussed.

Recommended Content:

Medical Surveillance Monthly Report

Outbreak of Acute Respiratory Illness Associated with Adenovirus Type 4 at the U.S. Naval Academy, 2016

Article
2/1/2019
Malaria case definition

Human adenoviruses (HAdVs) are known to cause respiratory illness outbreaks at basic military training (BMT) sites. HAdV type-4 and -7 vaccines are routinely administered at enlisted BMT sites, but not at military academies. During Aug.–Sept. 2016, U.S. Naval Academy clinical staff noted an increase in students presenting with acute respiratory illness (ARI). An investigation was conducted to determine the extent and cause of the outbreak. During 22 Aug.–11 Sept. 2016, 652 clinic visits for ARI were identified using electronic health records. HAdV-4 was confirmed by real-time polymerase chain reaction assay in 18 out of 33 patient specimens collected and 1 additional HAdV case was detected from hospital records. Two HAdV-4 positive patients were treated for pneumonia including 1 hospitalized patient. Molecular analysis of 4 HAdV-4 isolates identified genome type 4a1, which is considered vaccine-preventable. Understanding the impact of HAdV in congregate settings other than enlisted BMT sites is necessary to inform discussions regarding future HAdV vaccine strategy.

Recommended Content:

Medical Surveillance Monthly Report

Update: Malaria, U.S. Armed Forces, 2018

Article
2/1/2019
Anopheles merus

Malaria infection remains an important health threat to U.S. service mem­bers who are located in endemic areas because of long-term duty assign­ments, participation in shorter-term contingency operations, or personal travel. In 2018, a total of 58 service members were diagnosed with or reported to have malaria. This represents a 65.7% increase from the 35 cases identi­fied in 2017. The relatively low numbers of cases during 2012–2018 mainly reflect decreases in cases acquired in Afghanistan, a reduction due largely to the progressive withdrawal of U.S. forces from that country. The percentage of cases of malaria caused by unspecified agents (63.8%; n=37) in 2018 was the highest during any given year of the surveillance period. The percent­age of cases identified as having been caused by Plasmodium vivax (10.3%; n=6) in 2018 was the lowest observed during the 10-year surveillance period. The percentage of malaria cases attributed to P. falciparum (25.9 %) in 2018 was similar to that observed in 2017 (25.7%), although the number of cases increased. Malaria was diagnosed at or reported from 31 different medical facilities in the U.S., Afghanistan, Italy, Germany, Djibouti, and Korea. Pro­viders of medical care to military members should be knowledgeable of and vigilant for clinical manifestations of malaria outside of endemic areas.

Recommended Content:

Medical Surveillance Monthly Report

Update: Incidence of Glaucoma Diagnoses, Active Component, U.S. Armed Forces, 2013–2017

Article
2/1/2019
Glaucoma

Glaucoma is an eye disease that involves progressive optic nerve damage and vision loss, leading to blindness if undetected or untreated. This report describes an analysis using the Defense Medical Surveillance System to identify all active component service members with an incident diagnosis of glaucoma during the period between 2013 and 2017. The analysis identified 37,718 incident cases of glaucoma and an overall incidence rate of 5.9 cases per 1,000 person-years (p-yrs). The majority of cases (97.6%) were diagnosed at an early stage as borderline glaucoma; of these borderline cases, 2.2% progressed to open-angle glaucoma during the study period. No incident cases of absolute glaucoma, or total blindness, were identified. Rates of glaucoma were higher among non-Hispanic black (11.0 per 1,000 p-yrs), Asian/Pacific Islander (9.5), and Hispanic (6.9) service members, compared with non-Hispanic white (4.0) service members. Rates among female service members (6.6 per 1,000 p-yrs) were higher than those among male service members (5.8). Between 2013 and 2017, incidence rates of glaucoma diagnoses increased by 75.4% among all service members.

Recommended Content:

Medical Surveillance Monthly Report

Re-evaluation of the MSMR Case Definition for Incident Cases of Malaria

Article
2/1/2019
Anopheles merus

The MSMR has been publishing the results of surveillance studies of malaria since 1995. The standard MSMR case definition uses Medical Event Reports and records of hospitalizations in counting cases of malaria. This report summarizes the performance of the standard MSMR case definition in estimating incident cases of malaria from 2015 through 2017. Also explored was the potential surveillance value of including outpatient encounters with diagnoses of malaria or positive laboratory tests for malaria in the case definition. The study corroborated the relative accuracy of the MSMR case definition in estimating malaria incidence and provided the basis for updating the case definition in 2019 to include positive laboratory tests for malaria antigen within 30 days of an outpatient diagnosis.

Recommended Content:

Medical Surveillance Monthly Report

Thyroid Disorders, Active Component, U.S. Armed Forces, 2008–2017

Article
12/1/2018
A U.S. naval officer listens through his stethoscope to hear his patient’s lungs at Camp Schwab in Okinawa, Japan in 2018. (Photo courtesy of U.S. Marine Corps) photo by Lance Cpl. Cameron Parks)

This analysis describes the incidence and prevalence of five thyroid disorders (goiter, thyrotoxicosis, primary/not otherwise specified [NOS] hypothyroidism, thyroiditis, and other disorders of the thyroid) among active component service members between 2008 and 2017. During the 10-year surveillance period, the most common incident thyroid disorder among male and female service members was primary/NOS hypothyroidism and the least common were thyroiditis and other disorders of thyroid. Primary/NOS hypothyroidism was diagnosed among 8,641 females (incidence rate: 43.7 per 10,000 person-years [p-yrs]) and 11,656 males (incidence rate: 10.2 per 10,000 p-yrs). Overall incidence rates of all thyroid disorders were 3 to 5 times higher among females compared to males. Among both males and females, incidence of primary/NOS hypothyroidism was higher among non-Hispanic white service members compared with service members in other race/ethnicity groups. The incidence of most thyroid disorders remained stable or decreased during the surveillance period. Overall, the prevalence of most thyroid disorders increased during the first part of the surveillance period and then either decreased or leveled off.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Prevalence of the Metabolic Syndrome Using ICD-9 and ICD-10 Diagnostic Codes, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

This report uses ICD-9 and ICD-10 codes (277.7 and E88.81, respectively) for the metabolic syndrome (MetS) to summarize trends in the incidence and prevalence of this condition among active component members of the U.S. Armed Forces between 2002 and 2017. During this period, the crude overall incidence rate of MetS was 7.5 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, overall incidence rates were highest among Asian/Pacific Islanders, Air Force members, and warrant officers and were lowest among those of other/unknown race/ethnicity, Marine Corps members, and junior enlisted personnel and officers. During 2002–2017, the annual incidence rates of MetS peaked in 2009 at 11.6 cases per 100,000 p-yrs and decreased to 5.9 cases per 100,000 p-yrs in 2017. Annual prevalence rates of MetS increased steadily during the first 11 years of the surveillance period reaching a high of 38.9 per 100,000 active component service members in 2012, after which rates declined slightly to 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Adrenal Gland Disorders, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing's syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report
<< < ... 16 17 18 19 > >> 
Showing results 256 - 270 Page 18 of 19
Refine your search
Last Updated: October 20, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery